Compare National Beverage Corp. (FIZZ) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Incyte Corporation — how do they compare? National Beverage Corp. trades at $30.74 (market cap $2.89B), while Incyte Corporation trades at $113.22 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 7.9× National Beverage Corp.'s market cap, and Incyte Corporation is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and Incyte Corporation for 33 Days on average.
| FIZZ | INCY | |
|---|---|---|
Market Cap | $2.89B | $22.85B |
Volume | 553,950 | 1,927,029 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $129.93 |
52-Week Low | $29.20 | $83.80 |
Typical Hold Time | 33 Days | 33 Days |
Enterprise Value | $2.84B | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
National Beverage Corp. (FIZZ) trades at $30.36, up 2.57% today, showing mixed signals with a bullish technical outlook but bearish analyst sentiment. The stock faces margin pressure with recent earnings misses and declining revenue growth, though profitability metrics remain strong with 14.81% net margin and 40.13% ROE. Recent news highlights institutional buying and a $3.25 special dividend payment.
FIZZ presents a cautious investment case with strong profitability offset by growth challenges. The company's high ROE and solid margins provide fundamental support, but consecutive earnings misses and tariff-related margin compression create near-term headwinds. Analyst consensus leans bearish with 50% sell ratings, suggesting limited upside potential despite technical strength.
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
